[Special Stock] Miko's Subsidiary Obtains European Certification for 'Corona 19' Diagnostic Kit... "Promoting Sales Across Europe"

[Asia Economy Reporter Yoo Hyun-seok] Miko is showing strong performance. It appears that the news of its subsidiary, bio medical diagnostic company MikobioMed, obtaining European certification for a molecular diagnostic kit that can confirm infection with the novel coronavirus (COVID-19) has had an impact.

As of 1:41 PM on the 11th, Miko was trading at 8,940 KRW, up 11.06% (890 KRW) compared to the previous trading day.

On this day, MikobioMed, a subsidiary of Miko, announced that its molecular diagnostic kit capable of confirming COVID-19 infection received European certification on the 7th. The certified products include the PCR Kit nCoV-QS, a COVID-19 diagnostic test kit independently developed by MikobioMed, and the PREP Kit 16TU-CV19, a gene extraction kit.

A company official stated, "By introducing innovative technology and applying POCT (point-of-care testing), MikobioMed's equipment can diagnose within one hour, much faster than the existing diagnostic equipment's six-hour testing time. Unlike conventional equipment, the 4kg compact RT PCR device can be used in mobile testing sites, vehicles, airports, and ports. We also developed corresponding COVID-19 diagnostic kits (reagents), which enabled rapid certification acquisition."

With this European certification, the company expects to start sales throughout Europe, including Italy, and to promote exports to many countries recognizing the European certification.

This content was produced with the assistance of AI translation services.